Poziotinib’s Shift Of Focus To HER2 May Increase Approval Chances

Potential First-Line Therapy

 
• By Jung Won Shin
positive
No Specific Approved NSCLS Therapy So Far For HER2 Exon 20 Insertion Mutation • Source: Alamy

More from Clinical Trials

More from R&D